Discovery of quinazoline HPK1 inhibitors with high cellular potency-Reference-Cited by-同舟云学术

Discovery of quinazoline HPK1 inhibitors with high cellular potency

Published:2023-09 Issue: Volume:92 Page:117423
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Toure Momar,Johnson Theresa^ORCID,Li Bin,Schmidt Ralf,Ma Hong,Neagu Constantin,Lopez Andrea Unzue,Wang Yanping,Guler Satenig,Xiao YuFang,Henkes Renate,Ho Kevin,Zhang Susan,Chu Chia Lin,Gundra Uma Mahesh,Porichis Filippos,Li Long,Maurer Christine Katharina,Fang Zhizhou^ORCID,Musil Djordje^ORCID,DiPoto Maria^ORCID,Friis Emily,Jones Reinaldo,Jones Christopher,Cummings James,Chekler Eugene,Tanzer Eva Maria,Huck Bayard,Sherer Brian

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference22 articles.

1. (a) A. J. Korman, S. C. Garrett-Thomson, N. Lonber. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 21 (2022), 509-528).

2. (b) A. D. Waldman, J. M. Fritz, M. J. Lenardo. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20 (2020), 651-668.

3. a) M. C. Hu, W. R. Qiu, X. Wang, C. F. Meyer, T. H. Tan. Human HPK1, a novel human hematopoietic progenitor kinase that activates the JNK/SAPK kinase cascade, Genes Dev. 10 (1996), 2251-2264.

4. (b) J. S. Boomer, T. H. Tan. Functional interactions of HPK1 with adaptor proteins. J. Cell. Biochem. 95 (2005) 34-44.

5. Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell–mediated immune responses;Shui;Nat Immunol,2007

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress;Expert Opinion on Therapeutic Targets;2024-04-02

2. Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody;European Journal of Medicinal Chemistry;2024-03